Skip to content
OpenCapital
Get started

Celcuity CELC Debt Maturity - 2027

Debt Maturity - 2027 at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
——

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.4B+1,370%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree.

The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celcuity's debt maturity - 2027.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celcuity's debt maturity - 2027?
Celcuity (CELC) reported debt maturity - 2027 of $44.01M in Q1 2026.
How has Celcuity's debt maturity - 2027 changed year-over-year?
Celcuity's debt maturity - 2027 decreased by 16.4% year-over-year, from $52.61M to $44.01M.
What is the long-term trend for Celcuity's debt maturity - 2027?
Over 4 years (2021 to 2025), Celcuity's debt maturity - 2027 has grown at a 66.3% compound annual growth rate (CAGR), from $5.74M to $43.9M.
What does debt maturity - 2027 mean?
The specific principal amount of debt obligations scheduled to mature in the year 2027. This metric is essential for assessing the company's liquidity risk and refinancing requirements in a specific future period. It helps investors understand the timing of potential cash outflows related to debt repayment.